TrialJournal of immunology (Baltimore, Md. : 1950)2012

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Mark S de Souza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.